{"entity":{"id":"clsp-5282","kind":"drug","name":"CLSP-5282","aka":[],"tldr":"CLSP-5282 is an experimental T cell engager from Clasp Therapeutics, in phase 1 trials for KRAS G12V-mutant solid tumours in HLA-A*03:01-positive patients.","summary":"CLSP-5282 is a T cell engager from Clasp Therapeutics. A T cell engager designed to redirect T cells to tumours presenting the KRAS G12V peptide on HLA-A*03:01; the lead of the company's KRAS T cell engager portfolio. Its furthest stage is phase 1, for KRAS G12V-mutant solid tumours in HLA-A*03:01-positive patients (registry lists non-small cell lung, pancreatic and colorectal cancer). ClinicalTrials.gov registers it in one study linked below. SENTINEL-101 phase 1 NCT07650357 registered, NOT YET RECRUITING. The April 2026 release said the IND was expected in 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Clasp Therapeutics: clasptx.com","url":"https://www.clasptx.com/press-release-publications/clasp-therapeutics-unveils-first-in-class-kras-t-cell-engager-clsp-5282-at-aacr-2026"},{"label":"Clasp Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07650357"},{"label":"ClinicalTrials.gov: trials of CLSP-5282","url":"https://clinicaltrials.gov/search?intr=CLSP-5282"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["kras"],"drugs":[],"companies":["clasp-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07650357"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CLSP-5282","modality":"T cell engager","mechanism":"A T cell engager designed to redirect T cells to tumours presenting the KRAS G12V peptide on HLA-A*03:01; the lead of the company's KRAS T cell engager portfolio.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/clsp-5282/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"clasp-therapeutics","kind":"company","name":"Clasp Therapeutics","route":"/companies/clasp-therapeutics/"}],"trial":[{"id":"nct07650357","kind":"trial","name":"A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)","route":"/trials/nct07650357/"}]}}